Cognitive Impairment and Rehabilitation in Alzheimer’s Disease

  • Theodoros Angelopoulos
  • Dorothy Martha Scordilis
  • Christos TsagkarisEmail author


A wealth of evidence emphasizes on the link between Alzheimer’s disease (AD) and cognitive impairment (CI). CI is generally accepted as a decline in memory, learning capacity, concentration, or decision-making, leading to functional impairment. The role of mild cognitive impairment (MCI) as a predictive factor of AD and the CI linked to the establishment and progression of AD have been discussed in the context of epidemiology, genetics, pathophysiology, pathology, and clinical practice. AD-associated CI has been also addressed as a source of socioeconomic burden urging for the development of therapeutic interventions. Cognitive rehabilitation (CR) is a complementary non-pharmaceutical treatment for AD consisting of cognitive stimulation and training methods. Based on the neuronal plasticity concept, CR aims at increasing AD patients’ functional status and retarding their mental decline. Although the method has encouraging results in several studies, there is still controversy as far as its efficacy is concerned and further research ought to be conducted before incorporating CR in AD’s treatment plan globally. CR drawbacks should be addressed and counteracted in this context, while the current CR approach may be ameliorated through errorless learning techniques.


  1. Abbott RD et al (2004) Walking and dementia in physically capable elderly men. JAMA 292(12):1447–1453. Scholar
  2. Acevedo A, Loewenstein DA (2007) Nonpharmacological cognitive interventions in aging and dementia. J Geriatr Psychiatry Neurol 20(4):239–249. Scholar
  3. Albert MS et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):270–279. Scholar
  4. Alzheimer’s Association (2010) 2010 Alzheimer’s disease facts and figures. Alzheimers Dement 6(2):158–194. Scholar
  5. Bagyinszky E et al (2016) Mutations, associated with early-onset Alzheimer’s disease, discovered in Asian countries. Clin Interv Aging Volume 11:1467–1488. Scholar
  6. Bahar-Fuchs A, Clare L, Woods B (2013a) Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev 6:CD003260. Scholar
  7. Bahar-Fuchs A, Clare L, Woods B (2013b) Cognitive training and cognitive rehabilitation for persons with mild to moderate dementia of the Alzheimer’s or vascular type: a review. Alzheimers Res Ther 5(4):35. Scholar
  8. Ball K et al (2002) Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA 288(18):2271–2281. Available at: Accessed 13 Dec2018CrossRefGoogle Scholar
  9. Baumgart M et al (2015) Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement 11(6):718–726. Scholar
  10. Behrman S, Valkanova V, Allan CL (2017) Diagnosing and managing mild cognitive impairment. Practitioner 261(1804):17–20. Available at: Accessed 13 Dec 2018PubMedGoogle Scholar
  11. Bekris LM et al (2010) Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 23(4):213–227. Scholar
  12. Bidzan L, Bidzan M, Pąchalska M (2016) The effects of intellectual, physical, and social activity on further prognosis in mild cognitive impairment. Med Sci Monit 22:2551–2560. Available at: Accessed 13 Dec 2018CrossRefGoogle Scholar
  13. Bloom GS (2014) Amyloid-β and Tau. JAMA Neurol 71(4):505. Scholar
  14. Bottino CM et al (2005) Cognitive rehabilitation combined with drug treatment in Alzheimer’s disease patients: a pilot study. Clin Rehab 19(8):861–869. Scholar
  15. Casper LD et al (2015) 19th edition Harrison’s principles of internal medicine: volume II, 19th edn. McGraw-Hill Education, New York/Chicago/San Francisco/Athens/London/Madrid/Mexico City/Milan/New Delhi/Singapore/Sydney/TorontoGoogle Scholar
  16. Chiu C-C et al (2008) The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuro-Psychopharmacol Biol Psychiatry 32(6):1538–1544. Scholar
  17. Choi J, Twamley EW (2013) Cognitive rehabilitation therapies for Alzheimer’s disease: a review of methods to improve treatment engagement and self-efficacy. Neuropsychol Rev 23(1):48–62. Scholar
  18. Clare L, Woods RT (2004) Cognitive training and cognitive rehabilitation for people with early-stage Alzheimer’s disease: a review. Neuropsychol Rehabil 14(4):385–401. Scholar
  19. Clare L et al (2010) Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy. Am J Geriatr Psychiatry 18(10):928–939. Scholar
  20. Cognitive Rehabilitation Therapy | Tricare (n.d.). Available at: Accessed 13 Dec 2018
  21. Corder EH et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science (New York, NY) 261(5123):921–923. Available at: Accessed 13 Dec 2018CrossRefGoogle Scholar
  22. de Souza-Talarico JN et al (2016) Dementia and cognitive impairment prevalence and associated factors in indigenous populations. Alzheimer Dis Assoc Disord 30(3):281–287. Scholar
  23. De Strooper B et al (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391(6665):387–390. Scholar
  24. Dos Santos Picanço LC et al (2016) Alzheimer’s disease: a review from the pathophysiology to diagnosis, new perspectives for pharmacological treatment. Curr Med Chem 25(26):3141–3159. Available at: Accessed 13 Dec 2018CrossRefGoogle Scholar
  25. Engelhart MJ et al (2002) Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287(24):3223–3229. Available at: Accessed 13 Dec 2018CrossRefGoogle Scholar
  26. Féart C et al (2009) Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA 302(6):638. Scholar
  27. Fratiglioni L, Paillard-Borg S, Winblad B (2004) An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 3(6):343–353. Scholar
  28. Germain S et al (2018) Efficacy of cognitive rehabilitation in Alzheimer disease: a 1-year Follow-Up study. J Geriatr Psychiatry Neurol 32(13):089198871881372. Scholar
  29. Ginarte-Arias Y (n.d.) [Cognitive rehabilitation. Theoretical and methodological aspects]. Rev Neurol 35(9):870–876. Available at: Accessed 13 Dec 2018
  30. Goedert M (2015) Alzheimer’s and Parkinson’s diseases: the prion concept in relation to assembled A, tau, and -synuclein. Science 349(6248):1255555. Scholar
  31. Goldman L, Schafer IA (2012) In: Goldman L, Schafer A (eds) Goldman-cecil medicine 25th edition volume I, 25th edn. Elsevier Seaunders, PhiladelphiaGoogle Scholar
  32. Gouras GK, Olsson TT, Hansson O (2015) β-Amyloid peptides and amyloid plaques in Alzheimer’s disease. Neurotherapeutics 12(1):3–11. Scholar
  33. Haier RJ et al (1992) Regional glucose metabolic changes after learning a complex visuospatial/motor task: a positron emission tomographic study. Brain Res 570(1–2):134–143. Available at: Accessed 13 Dec 2018CrossRefGoogle Scholar
  34. Heiss WD et al (n.d.) Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer’s disease. A neuropsychological, EEG, and PET investigation. Dementia (Basel, Switzerland) 5(2):88–98. Available at: Accessed 13 Dec 2018
  35. Hwang J-H, Cha H-G, Cho H-S (2015) The effects of cognitive rehabilitation on Alzheimer’s dementia patients’ cognitive assessment reference diagnosis system performance based on level of cognitive functioning. J Phys Ther Sci 27(9):2875–2877. Scholar
  36. Jacquemin A (2009) Strategy and methods of cognitive rehabilitation in patients with Alzheimer’s disease or other dementia. Psychol Neuropsychiatr Vieil 7(4):265–273. Scholar
  37. Jeong S (2017) Molecular and cellular basis of neurodegeneration in Alzheimer’s disease. Mol Cell 40(9):613–620. Scholar
  38. Jicha GA, Carr SA (2010) Conceptual evolution in Alzheimer’s disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease. J Alzheimers Dis 19(1):253–272. Scholar
  39. Kelly ME, Maria BO (2015) Strategies and techniques for cognitive rehabilitation manual for healthcare professionals working with individuals with cognitive impairment. Available at: Accessed 12 Dec 2018
  40. Krogsboll L, Jorgensesn K, Larsen C (2012) General health checks in adults for reducing morbidity and mortality from disease: conchrane systematic review and meta-analysis. BMJ 345:e7191CrossRefGoogle Scholar
  41. Kurz A et al (1996) Apolipoprotein E type 4 allele and Alzheimer’s disease: effect on age at onset and relative risk in different age groups. J Neurol 243(6):452–456. Available at: Accessed 13 Dec 2018CrossRefGoogle Scholar
  42. Langa KM, Levine DA (2014) The diagnosis and management of mild cognitive impairment. JAMA 312(23):2551. Scholar
  43. Larson EB, Kukull WA, Katzman RL (1992) Cognitive impairment: dementia and Alzheimer’s disease. Annu Rev Public Health 13(1):431–449. Scholar
  44. Laurin D et al (2004) Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study. Am J Epidemiol 159(10):959–967. Available at: Accessed 13 Dec 2018CrossRefGoogle Scholar
  45. Limond J, Leeke R (2005) Practitioner review: cognitive rehabilitation for children with acquired brain injury. J Child Psychol Psychiatry 46(4):339–352. Scholar
  46. Liu C-C et al (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9(2):106–118. Scholar
  47. Loewenstein DA et al (2004) Cognitive rehabilitation of mildly impaired Alzheimer disease patients on cholinesterase inhibitors. Am J Geriatr Psychiatry 12(4):395–402. Scholar
  48. Marešová P, Zahálková V (2016) The economic burden of the care and treatment for people with Alzheimer’s disease: the outlook for the Czech Republic. Neurol Sci 37(12):1917–1922. Scholar
  49. Middleton EL, Schwartz MF (2012) Errorless learning in cognitive rehabilitation: a critical review. Neuropsychol Rehabil 22(2):138–168. Scholar
  50. Morris MC et al (2002) Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 287(24):3230–3237. Available at: Accessed 13 Dec 2018CrossRefGoogle Scholar
  51. Mufson EJ et al (2012) Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol 123(1):13–30. Scholar
  52. Mufson EJ et al (2016) Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment. Neurobiol Aging 37:147–153. Scholar
  53. Myers RH et al (1996) Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study. Neurology 46(3):673–677. Available at: Accessed 13 Dec2018CrossRefGoogle Scholar
  54. Nicolas G et al (2018) Somatic variants in autosomal dominant genes are a rare cause of sporadic Alzheimer’s disease. Alzheimers Dement 14(12):1632–1639. Scholar
  55. Petersen RC et al (2014) Mild cognitive impairment: a concept in evolution. J Intern Med 275(3):214–228. Scholar
  56. Pierce AL, Bullain SS, Kawas CH (2017) Late-onset Alzheimer disease. Neurol Clin 35(2):283–293. Scholar
  57. Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7(3):137–152. Scholar
  58. Rogaeva E et al (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39(2):168–177. Scholar
  59. Sachdev PS et al (2014) Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol 10(11):634–642. Scholar
  60. Scheuner D et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 2(8):864–870. Available at: Accessed 13 Dec 2018CrossRefGoogle Scholar
  61. Singh B et al (2014) Association of mediterranean diet with mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 39(2):271–282. Scholar
  62. Stephan BCM et al (2012) The neuropathological profile of mild cognitive impairment (MCI): a systematic review. Mol Psychiatry 17(11):1056–1076. Scholar
  63. Takahashi RH, Nagao T, Gouras GK (2017) Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer’s disease. Pathol Int 67(4):185–193. Scholar
  64. Takao M (2012) [Neuropathology of mild cognitive impairment]. Rinsho Shinkeigaku 52(11):851–854. Available at: Accessed 13 Dec 2018CrossRefGoogle Scholar
  65. Takizawa C et al (2014) Epidemiological and economic burden of Alzheimer’s disease: a systematic literature review of data across Europe and the United States of America. J Alzheimers Dis 43(4):1271–1284. Scholar
  66. Verghese A, Brady E, Kapur C (2011) The bedside evaluation: ritual and reason. Ann Intern Med 155:550–553CrossRefGoogle Scholar
  67. Viola LF et al (2011) Effects of a multidisciplinary cognitive rehabilitation program for patients with mild Alzheimer’s disease. Clinics (Sao Paulo) 66(8):1395–1400. Available at: Accessed 13 Dec 2018CrossRefGoogle Scholar
  68. Wetterling T, Kanitz RD, Borgis KJ (1996) Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 27(1):30–36. Available at: Accessed 13 Dec 2018CrossRefGoogle Scholar
  69. Winocur G et al (2000) Cognitive rehabilitation in clinical neuropsychology. Brain Cogn 42(1):120–123. Scholar
  70. Wu L et al (2012) Early-onset familial Alzheimer’s disease (EOFAD). Can J Neurol Sci 39(4):436–445. Available at: Accessed 13 Dec 2018CrossRefGoogle Scholar
  71. Xu W et al (2017) Alcohol consumption and dementia risk: a dose–response meta-analysis of prospective studies. Eur J Epidemiol 32(1):31–42. Scholar
  72. Yehuda S et al (n.d.) The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol Aging 23(5):843–853. Available at: Accessed 13 Dec 2018

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Theodoros Angelopoulos
    • 1
  • Dorothy Martha Scordilis
    • 2
  • Christos Tsagkaris
    • 1
    Email author
  1. 1.Faculty of MedicineUniversity of CreteHeraklionGreece
  2. 2.Faculty of MedicineMedical University of SofiaSofiaBulgaria

Personalised recommendations